Published in Curr Opin Infect Dis on December 01, 2010
Chagas disease: "the new HIV/AIDS of the Americas". PLoS Negl Trop Dis (2012) 1.92
Host metabolism regulates intracellular growth of Trypanosoma cruzi. Cell Host Microbe (2013) 1.57
Accelerating the development of a therapeutic vaccine for human Chagas disease: rationale and prospects. Expert Rev Vaccines (2012) 1.21
Diverse inhibitor chemotypes targeting Trypanosoma cruzi CYP51. PLoS Negl Trop Dis (2012) 1.12
The Trypanosoma cruzi protease cruzain mediates immune evasion. PLoS Pathog (2011) 0.96
Organocatalytic, enantioselective synthesis of VNI: a robust therapeutic development platform for Chagas, a neglected tropical disease. Org Lett (2012) 0.92
Sequential combined treatment with allopurinol and benznidazole in the chronic phase of Trypanosoma cruzi infection: a pilot study. J Antimicrob Chemother (2012) 0.89
Evaluation of arylimidamides DB1955 and DB1960 as candidates against visceral leishmaniasis and Chagas' disease: in vivo efficacy, acute toxicity, pharmacokinetics, and toxicology studies. Antimicrob Agents Chemother (2012) 0.88
Di-cationic arylimidamides act against Neospora caninum tachyzoites by interference in membrane structure and nucleolar integrity and are active against challenge infection in mice. Int J Parasitol Drugs Drug Resist (2012) 0.87
Natural products as a source for treating neglected parasitic diseases. Int J Mol Sci (2013) 0.87
Biological and structural characterization of Trypanosoma cruzi phosphodiesterase C and Implications for design of parasite selective inhibitors. J Biol Chem (2012) 0.86
Automated high-content assay for compounds selectively toxic to Trypanosoma cruzi in a myoblastic cell line. PLoS Negl Trop Dis (2015) 0.84
Antiparasitic Effect of Vitamin B12 on Trypanosoma cruzi. Antimicrob Agents Chemother (2012) 0.84
Advances in imaging of animal models of Chagas disease. Adv Parasitol (2011) 0.83
Utilizing Chemical Genomics to Identify Cytochrome b as a Novel Drug Target for Chagas Disease. PLoS Pathog (2015) 0.83
Translational challenges of animal models in Chagas disease drug development: a review. Drug Des Devel Ther (2015) 0.83
Gene expression study using real-time PCR identifies an NTR gene as a major marker of resistance to benzonidazole in Trypanosoma cruzi. Parasit Vectors (2011) 0.82
Proteomic analysis of Trypanosoma cruzi response to ionizing radiation stress. PLoS One (2014) 0.81
Experimental Chemotherapy for Chagas Disease: A Morphological, Biochemical, and Proteomic Overview of Potential Trypanosoma cruzi Targets of Amidines Derivatives and Naphthoquinones. Mol Biol Int (2011) 0.78
Pharmacophore modeling for anti-Chagas drug design using the fragment molecular orbital method. PLoS One (2015) 0.78
Chagas disease. Lancet (2010) 10.25
Evaluation and treatment of chagas disease in the United States: a systematic review. JAMA (2007) 5.22
Efficient technique for screening drugs for activity against Trypanosoma cruzi using parasites expressing beta-galactosidase. Antimicrob Agents Chemother (1996) 3.62
A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes. Proc Natl Acad Sci U S A (2008) 2.54
Specific chemotherapy of Chagas disease: relevance, current limitations and new approaches. Acta Trop (2009) 2.37
Activities of the triazole derivative SCH 56592 (posaconazole) against drug-resistant strains of the protozoan parasite Trypanosoma (Schizotrypanum) cruzi in immunocompetent and immunosuppressed murine hosts. Antimicrob Agents Chemother (2000) 1.87
Ergosterol biosynthesis and drug development for Chagas disease. Mem Inst Oswaldo Cruz (2009) 1.84
Successful treatment with posaconazole of a patient with chronic Chagas disease and systemic lupus erythematosus. Am J Trop Med Hyg (2010) 1.77
Current treatment approaches to leishmaniasis. Curr Opin Infect Dis (2003) 1.74
Rational modification of a candidate cancer drug for use against Chagas disease. J Med Chem (2009) 1.73
In vitro and in vivo experimental models for drug screening and development for Chagas disease. Mem Inst Oswaldo Cruz (2010) 1.71
Chagas disease: pushing through the pipeline. Nature (2010) 1.57
African trypanosomiasis. Ann Trop Med Parasitol (2006) 1.55
Feasibility, drug safety, and effectiveness of etiological treatment programs for Chagas disease in Honduras, Guatemala, and Bolivia: 10-year experience of Médecins Sans Frontières. PLoS Negl Trop Dis (2009) 1.54
The BENEFIT trial: testing the hypothesis that trypanocidal therapy is beneficial for patients with chronic Chagas heart disease. Mem Inst Oswaldo Cruz (2009) 1.54
New, improved treatments for Chagas disease: from the R&D pipeline to the patients. PLoS Negl Trop Dis (2009) 1.42
Two approaches to discovering and developing new drugs for Chagas disease. Mem Inst Oswaldo Cruz (2009) 1.41
The activities of four anticancer alkyllysophospholipids against Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei. J Antimicrob Chemother (1996) 1.37
Peptide-fluoromethyl ketones arrest intracellular replication and intercellular transmission of Trypanosoma cruzi. Mol Biochem Parasitol (1993) 1.31
Treatment of leishmaniasis with miltefosine: 2008 status. Expert Opin Drug Metab Toxicol (2008) 1.30
A nonazole CYP51 inhibitor cures Chagas' disease in a mouse model of acute infection. Antimicrob Agents Chemother (2010) 1.22
Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment. Antimicrob Agents Chemother (2010) 1.20
Novel azasterols as potential agents for treatment of leishmaniasis and trypanosomiasis. Antimicrob Agents Chemother (2004) 1.12
Structurally simple inhibitors of lanosterol 14alpha-demethylase are efficacious in a rodent model of acute Chagas disease. J Med Chem (2009) 1.10
Identification of three classes of heteroaromatic compounds with activity against intracellular Trypanosoma cruzi by chemical library screening. PLoS Negl Trop Dis (2009) 1.09
In vitro and in vivo activity of lignan lactones derivatives against Trypanosoma cruzi. Parasitol Res (2006) 1.09
The effects on Trypanosoma cruzi of novel synthetic naphthoquinones are mediated by mitochondrial dysfunction. Free Radic Biol Med (2009) 1.09
Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi. Antimicrob Agents Chemother (2010) 1.07
Nonpeptidic tetrafluorophenoxymethyl ketone cruzain inhibitors as promising new leads for Chagas disease chemotherapy. J Med Chem (2010) 1.00
A comparative study of posaconazole and benznidazole in the prevention of heart damage and promotion of trypanocidal immune response in a murine model of Chagas disease. Int J Antimicrob Agents (2010) 0.99
Novel ruthenium complexes as potential drugs for Chagas's disease: enzyme inhibition and in vitro/in vivo trypanocidal activity. Br J Pharmacol (2010) 0.98
Complexation of the anti-Trypanosoma cruzi drug benznidazole improves solubility and efficacy. J Med Chem (2008) 0.98
Metal complexes as chemotherapeutic agents against tropical diseases: trypanosomiasis, malaria and leishmaniasis. Mini Rev Med Chem (2004) 0.97
Diamidine activity against trypanosomes: the state of the art. Curr Mol Pharmacol (2008) 0.96
Nitric oxide donor trans-[RuCl([15]aneN)NO] as a possible therapeutic approach for Chagas' disease. Br J Pharmacol (2010) 0.96
Binding of nitrogen-containing bisphosphonates (N-BPs) to the Trypanosoma cruzi farnesyl diphosphate synthase homodimer. Proteins (2010) 0.93
Phase I/II evaluation of the prophylactic antimalarial activity of pafuramidine in healthy volunteers challenged with Plasmodium falciparum sporozoites. Am J Trop Med Hyg (2009) 0.93
In vitro and in vivo trypanocidal effects of the cyclopalladated compound 7a, a drug candidate for treatment of Chagas' disease. Antimicrob Agents Chemother (2010) 0.93
In vitro susceptibility of Trypanosoma cruzi strains from Santander, Colombia, to hexadecylphosphocholine (miltefosine), nifurtimox and benznidazole. Biomedica (2009) 0.92
Synthesis and characterization of potent inhibitors of Trypanosoma cruzi dihydrofolate reductase. Bioorg Med Chem (2010) 0.91
New potent 5-nitroindazole derivatives as inhibitors of Trypanosoma cruzi growth: synthesis, biological evaluation, and mechanism of action studies. Bioorg Med Chem (2009) 0.90
Actions of a proline analogue, L-thiazolidine-4-carboxylic acid (T4C), on Trypanosoma cruzi. PLoS One (2009) 0.89
Trypanosoma cruzi: activity of heterocyclic cationic molecules in vitro. Exp Parasitol (2009) 0.89
Second generation of 2H-benzimidazole 1,3-dioxide derivatives as anti-trypanosomatid agents: synthesis, biological evaluation, and mode of action studies. Eur J Med Chem (2009) 0.88
Trypanocidal activity and acute toxicity assessment of triterpene acids. Parasitol Res (2010) 0.87
Biological, ultrastructural effect and subcellular localization of aromatic diamidines in Trypanosoma cruzi. Parasitology (2009) 0.87
Synthesis and characterization of a pyridine-2-thiol N-oxide gold(I) complex with potent antiproliferative effect against Trypanosoma cruzi and Leishmania sp. insight into its mechanism of action. J Inorg Biochem (2009) 0.87
Effects of the calpain inhibitor MDL28170 on the clinically relevant forms of Trypanosoma cruzi in vitro. J Antimicrob Chemother (2010) 0.86
Experimental chemotherapy against Trypanosoma cruzi infection using ruthenium nitric oxide donors. Antimicrob Agents Chemother (2009) 0.86
Neolignans from plants in northeastern Brazil (Lauraceae) with activity against Trypanosoma cruzi. Exp Parasitol (2009) 0.85
Antitrypanosomal and antileishmanial activities of novel N-alkyl-(1-phenylsubstituted-beta-carboline)-3-carboxamides. Biomed Pharmacother (2010) 0.85
Reduction of parasitism tissue by treatment of mice chronically infected with Trypanosoma cruzi with lignano lactones. Parasitol Res (2010) 0.84
New potent imidazoisoquinolinone derivatives as anti-Trypanosoma cruzi agents: biological evaluation and structure-activity relationships. Bioorg Med Chem (2009) 0.84
SAR studies on azasterols as potential anti-trypanosomal and anti-leishmanial agents. Bioorg Med Chem (2009) 0.82
Discovery of novel Trypanosoma cruzi glyceraldehyde-3-phosphate dehydrogenase inhibitors. Bioorg Med Chem (2009) 0.81
Antitrypanosomal activity of a diterpene and lignans isolated from Aristolochia cymbifera. Planta Med (2010) 0.81
In vitro effect of a new cinnamic acid derivative against the epimastigote form of Trypanosoma cruzi. Arzneimittelforschung (2009) 0.80
(-)-Hinokinin-loaded poly(D,-lactide-co-glycolide) microparticles for Chagas disease. Parasitol Res (2010) 0.80
Naftifine-analogues as anti-Trypanosoma cruzi agents. Eur J Med Chem (2010) 0.79
The evaluation of quinonoid compounds against Trypanosoma cruzi: synthesis of imidazolic anthraquinones, nor-beta-lapachone derivatives and beta-lapachone-based 1,2,3-triazoles. Bioorg Med Chem (2010) 0.78
5-Nitro-2-furyl derivative actives against Trypanosoma cruzi: preliminary in vivo studies. Eur J Med Chem (2009) 0.77